Resources Repository
-
ReviewPublication 2016Using Economic Evidence to Set Healthcare Priorities in LMIC
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks …
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks for identifying priority health interventions. This paper synthesizes and appraises the literature on methodological frameworks – which incorporate economic evaluation evidence – for the purpose of setting healthcare priorities in LMICs. A systematic search of Embase, MEDLINE, Econlit and PubMed identified 3968 articles with a further 21 articles identified through manual searching. A total of 36 papers were eligible for inclusion.…
Benefit-Cost Analysis | Middle East & North Africa | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean | Asia & Pacific -
ReviewPublication 2015Population Health: Behavioral and Social Science Insights
This book comprises 23 chapters focused on what the effects of various behavioral and social factors …
This book comprises 23 chapters focused on what the effects of various behavioral and social factors on longevity, disability and illness, and quality of life, primarily at the population level. Factors such as access to health care, educational attainment, nutrition, physical activity, use of tobacco products, and non-communicable diseases are considered, along with many other determinants of health and longevity. Of particular interest for health decision scientists are the following chapters: In Section 4: The Science…
Benefit-Cost Analysis | Global | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | North America | Europe -
ReviewPublication 2014Valuing Vaccination
Vaccination has led to remarkable health gains over the last century. However, large coverage gaps …
Vaccination has led to remarkable health gains over the last century. However, large coverage gaps remain, which will require significant financial resources and political will to address. In recent years, a compelling line of inquiry has established the economic benefits of health, at both the individual and aggregate levels. Most existing economic evaluations of particular health interventions fail to account for this new research, leading to potentially sizable undervaluation of those interventions. In line with…
Benefit-Cost Analysis | Global | Preferences/Values | Priority Setting/Ethics | Costing Methods | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine -
ReviewPublication 2012Modeling Preventative Strategies Against HPV-Related Disease in Developed Countries
This review article is part of a special supplement on “Comprehensive Control of HPV Infections …
This review article is part of a special supplement on “Comprehensive Control of HPV Infections and Related Diseases.” At the time of its writing, prophylactic vaccination against human papillomavirus (HPV) in pre-adolescent females had been introduced in most developed countries, supported by modeled evaluations that had almost universally found vaccination of pre-adolescent females to be cost-effective. Vaccination of pre-adolescent males had been shown to be cost-effective at a cost per vaccinated individual of ~US$400-500 if…
Mathematical Models | Global | Cost-Effectiveness Analysis | Chronic Disease/Risk | Social Determinants | Health Systems | Health/Medicine -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Mathematical Models | Global | Decision Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Science/Technology -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Mathematical Models | Global | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Policy/Regulation | Health/Medicine